Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Free Report) insider Todd Alfred Carter sold 10,500 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $8.16, for a total transaction of $85,680.00. Following the transaction, the insider now directly owns 54,360 shares of the company’s stock, valued at approximately $443,577.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Todd Alfred Carter also recently made the following trade(s):
- On Thursday, July 6th, Todd Alfred Carter sold 5,500 shares of Voyager Therapeutics stock. The shares were sold at an average price of $10.80, for a total transaction of $59,400.00.
Voyager Therapeutics Stock Performance
Shares of VYGR stock opened at $8.16 on Tuesday. The company has a market cap of $358.00 million, a P/E ratio of 3.59 and a beta of 1.03. The stock has a 50 day simple moving average of $9.25 and a two-hundred day simple moving average of $9.60. Voyager Therapeutics, Inc. has a fifty-two week low of $4.77 and a fifty-two week high of $14.34.
Institutional Investors Weigh In On Voyager Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the company. Armistice Capital LLC increased its position in shares of Voyager Therapeutics by 3.8% during the first quarter. Armistice Capital LLC now owns 3,524,000 shares of the company’s stock worth $27,170,000 after acquiring an additional 128,000 shares in the last quarter. HarbourVest Partners LLC bought a new stake in shares of Voyager Therapeutics during the first quarter worth about $476,000. Globeflex Capital L P bought a new stake in shares of Voyager Therapeutics during the first quarter worth about $278,000. Farallon Capital Management LLC bought a new stake in shares of Voyager Therapeutics during the first quarter worth about $6,145,000. Finally, Hershey Trust Co. bought a new stake in Voyager Therapeutics during the first quarter worth $97,000. Institutional investors own 58.81% of the company’s stock.
Analyst Ratings Changes
VYGR has been the subject of a number of analyst reports. StockNews.com initiated coverage on Voyager Therapeutics in a research report on Thursday, August 17th. They set a “hold” rating for the company. Oppenheimer restated an “outperform” rating and set a $16.00 price objective on shares of Voyager Therapeutics in a research report on Monday, August 7th.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease.
- Five stocks we like better than Voyager Therapeutics
- The How and Why of Investing in Biotech Stocks
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- What Does the Consumer Price Index Measure?
- 5 Reasons Mullen Automotive is About to Turn a Corner
- How to Find Undervalued Stocks
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.